The Cure Leukaemia Team

Based in the heart of the West Midlands, the Cure Leukaemia fundraising team work closely with our Doctors, Nurses, Fundraisers, Corporate partners and supporters day in, day out to fund the work of Professor Charlie Craddock CBE and his team at the internationally significant Centre for Clinical Haematology.

 

 

James McLaughlin

Chief Executive

Twitter: @Mc73James

 

 

Jackie Kelly

Head of Corporate Partnerships

Email: Jackie@cureleukaemia.co.uk

 

 

Joe White

Partnerships and Events Manager

Email: Joe@cureleukaemia.co.uk

 

 

Jennie Hoye

Accounts & Fundraising Assistant

Email: Jennie@cureleukaemia.co.uk

 

 

Andrew Wilkes

Head of Finance

Email: Andrew@cureleukaemia.co.uk

 

Email us

If you are interested in fundraising for Cure Leukaemia or finding out more about the work being done by the charity, please email info@cureleukaemia.co.uk

For media enquiries please email ben@cureleukaemia.co.uk

If you are a business and would like to find out more about becoming an official charity partner, please email jackie@cureleukaemia.co.uk

 

Phone us

Please note that we do not have an office landline now. If you would like to speak to one of the team, please contact info@cureleukaemia.co.uk.

Write to us

If you have a cheque, gift aid form or any other form of communication you would like to send to us, our office details are below:

Cure Leukaemia
PO Box 18280
Solihull
B90 9NA

Clinic details

Centre for Clinical Haematology
Queen Elizabeth Hospital
Edgbaston
Birmingham
B15 2TH

What we do

The Trials Acceleration Programme (TAP)

How funds raised for Cure Leukaemia help save lives

Cure Leukamia Pre footer image
"Cure Leukaemia’s funding of the UK Trials Acceleration Programme (TAP) is a game-changer and increases the access for blood cancer patients to potentially transformative new therapies."

Sir John Bell
"Cure Leukaemia’s funding of the UK Trials Acceleration Programme (TAP) is a game-changer and increases the access for blood cancer patients to potentially transformative new therapies."

Sir John Bell